← Leaderboards
Samia Mora
Brigham And Women'S Hospital
$13,080,456
Attributed
$14,527,755
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,527,755 · 7
By mechanism
R01$12,729,023 · 4
K24$980,902 · 1
K08$549,330 · 1
R21$268,500 · 1
Top collaborators
- Frank B Hu4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Kenneth M Kaye$21,944,697
- Hyon K Choi$12,976,398
- Naomi D Fisher$3,265,682
- Lynn Bry$10,918,358
- Robert J Glynn$12,512,252
Others in their field
Top investigators on “Event”
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Francis L Halzen · University Of Wisconsin-Madison$229,314,069
Research focus
EventLipidsCardiovascular SystemCost EffectiveProspectiveFuturePlacebosWomanBiological MarkersCase ControlRandomizedRisk FactorsInterestCardiovascular DiseasesCardiovascular Disorder RiskPathway InteractionsClinical TrialsPreventPrimary PreventionBaseDesignCardiovascular Risk FactorPhenotypeChronic
Grant awards (37)
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention$755,921
R01 · FY2025 · HL · contact PI
Mentored Patient-Oriented Research for Preventing ASCVD Events$126,184
K24 · FY2025 · HL · contact PI
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention$742,480
R01 · FY2024 · HL · contact PI
Mentored Patient-Oriented Research for Preventing ASCVD Events$126,184
K24 · FY2024 · HL · contact PI
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention$759,294
R01 · FY2023 · HL · contact PI
Mentored Patient-Oriented Research for Preventing ASCVD Events$126,184
K24 · FY2023 · HL · contact PI
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention$781,070
R01 · FY2022 · HL · contact PI
Total plasma and IgG glycomes, statin therapy and ASCVD events$447,500
R01 · FY2022 · HL · contact PI
Machine learning risk stratification in patients with ASCVD: A personalized approach$134,250
R21 · FY2022 · HL · contact PI
Patient Centered Approaches to Preventing ASCVD Events$120,470
K24 · FY2022 · HL · contact PI
Circulating plasma metabolites, diet, and risk of type 2 diabetes$711,401
R01 · FY2021 · DK
Total plasma and IgG glycomes, statin therapy and ASCVD events$447,500
R01 · FY2021 · HL · contact PI
Machine learning risk stratification in patients with ASCVD: A personalized approach$134,250
R21 · FY2021 · HL · contact PI
Patient Centered Approaches to Preventing ASCVD Events$120,470
K24 · FY2021 · HL · contact PI
Circulating plasma metabolites, diet, and risk of type 2 diabetes$713,972
R01 · FY2020 · DK
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid Pathways$710,610
R01 · FY2020 · HL · contact PI
Total plasma and IgG glycomes, statin therapy and ASCVD events$447,500
R01 · FY2020 · HL · contact PI
Patient Centered Approaches to Preventing ASCVD Events$120,470
K24 · FY2020 · HL · contact PI
Circulating plasma metabolites, diet, and risk of type 2 diabetes$712,883
R01 · FY2019 · DK
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid Pathways$700,806
R01 · FY2019 · HL · contact PI
Total plasma and IgG glycomes, statin therapy and ASCVD events$447,500
R01 · FY2019 · HL · contact PI
Patient Centered Approaches to Preventing ASCVD Events$120,470
K24 · FY2019 · HL · contact PI
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid Pathways$118,579
R01 · FY2019 · HL · contact PI
Circulating plasma metabolites, diet, and risk of type 2 diabetes$756,343
R01 · FY2018 · DK
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid Pathways$697,256
R01 · FY2018 · HL · contact PI
Patient Centered Approaches to Preventing ASCVD Events$120,470
K24 · FY2018 · HL · contact PI
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid Pathways$738,464
R01 · FY2017 · HL · contact PI
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes$443,750
R01 · FY2016 · HL · contact PI
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes$436,786
R01 · FY2015 · HL · contact PI
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes$433,343
R01 · FY2014 · HL · contact PI
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes$180,551
R01 · FY2014 · HL · contact PI
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes$125,741
R01 · FY2014 · HL · contact PI
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes$419,773
R01 · FY2013 · HL · contact PI
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy$137,850
K08 · FY2012 · HL · contact PI
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy$137,970
K08 · FY2011 · HL · contact PI
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy$137,160
K08 · FY2010 · HL · contact PI
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy$136,350
K08 · FY2009 · HL · contact PI